Rickard Sandin

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi‐Long Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017 · 1.2K citations

Oncology, Pathology, Bronchial Neoplasm +9

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

Thomas Wahlgren, Ulrika Harmenberg, Per Sandström et al. · British Journal of Cancer · 2013 · 105 citations · Full text

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2

Anne Vest Soerensen, Frede Donskov, Gregers G. Hermann et al. · European Journal of Cancer · 2013 · 76 citations · Full text

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Scott T. Tagawa, Krishnan Ramaswamy, Ahong Huang et al. · Prostate Cancer and Prostatic Diseases · 2021 · 57 citations · Full text

Methods for Adjusting for Bias Due to Crossover in Oncology Trials

K. Jack Ishak, Irina Proskorovsky, Beata Korytowsky et al. · PharmacoEconomics · 2014 · 55 citations

Oncology Trials, Meta-analysis, Medicine +10